Vinorelbine Ditartrate

长春瑞滨双酒石酸盐

Report date: 2026/03/17 20:00:15
NME

Base Information

Drug NameVinorelbine Ditartrate
Drug Alias NameVinorelbina Ditartrate酒石酸长春瑞滨Vinorelbinum Ditartrate去甲长春花碱Vinorelbine Tartrate +[13] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTubulin polymerisation inhibitors
TargetsTubulin
Therapy Area/IndicationsMetastatic breast cancerSkin MelanomaLow-grade Glioma +[19] 
Global Approved IndicationsCarcinoma, Non-Small-Cell LungBreast Neoplasms
Approved Indications in ChinaCarcinoma, Non-Small-Cell LungBreast Neoplasms
Original Approved Country/TerritoryUnited States
Original Approved Date1994/12/23
Country/TerritoryCanadaUnited StatesTaiwan +[14] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesPierre Fabre Group
China Registration ClassN/A

Develop Information

Active CompaniesJiangsu Hansoh Pharmaceutical Group Co LtdBeijing Diacrid Medical Technology Co LtdTopfond Pharmaceutical Co Ltd
Inactive CompaniesPierre Fabre LaboratoriesDana-Farber Cancer InstituteQlt Inc +[17] 
Active IndicationsMetastatic breast cancerCarcinoma, Non-Small-Cell LungBreast Neoplasms
Inactive IndicationsSkin MelanomaLow-grade GliomaCNS Embryonal Tumor +[16] 

Other Information

ATC CodeL01CA04
Related LinksWikipediaDrugBankKEGG